Author

M. U. Sheth

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:gene regulatory network inference· 1 Organism:non-human primate· 1

Frequent Co-Authors

K. E. Ware· 3 shared A. J. Armstrong· 2 shared B. C. Thomas· 2 shared D. L. Corcoran· 2 shared J. A. Somarelli· 2 shared J. Somarelli· 2 shared N. Hawkey· 2 shared S. Y. Kim· 2 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

K. E. Ware

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer

K. E. Ware, B. C. Thomas, P. Olawuni, M. U. Sheth, N. Hawkey, Y. M, B. C. Miller, K. Vietor, M. K. Jolly, S. Y. Kim, A. J. Armstrong, J. A. Somarelli

The paper identifies JAK/STAT signaling as a therapeutic target for Snail-induced enzalutamide-resistant prostate cancer through synthetic lethal screens and validation in a resistant cell model.

Frontiers in Molecular Biosciences · May 9, 2023Peer-reviewedCancer Biology

Loss of the chromatin remodeler, ATRX, promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin receptor binding

S. Bartholf DeWitt, S. Hoskinson Plumlee, H. E. Brighton, D. Sivaraj, E. J. Martz, M. Zand, V. Kumar, M. U. Sheth, W. Floyd, J. Spruance, N. Hawkey, S. Varghese, J. Ruan, D. G. Kirsch, J. Somarelli, , W. C. Eward

This study shows that loss of ATRX in osteosarcoma promotes aggressive tumor features through NF-κB signaling and integrin receptor binding, suggesting new therapeutic targets.

bioRxiv · Apr 22, 2022 · PreprintCancer Biology

Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes

K. E. Ware, S. Gupta, J. Eng, G. Kemeny, B. J. Puviindran, W.-C. Foo, L. A. Crawford, R. G. Almquist, D. Runyambo, B. C. Thomas, M. U. Sheth, A. Agarwal, M. Pierobon, E. F. Petricoin, D. L. Corcoran, , J. Somarelli

This study identifies p38/MAPK pathway activation as a convergent mechanism driving survival, immune evasion, and metastasis in hormone-resistant prostate cancer.

bioRxiv · Apr 22, 2020 · PreprintCancer Biology

From the clinic to the bench and back again in one dog year: identifying new treatments for sarcoma using a cross-species personalized medicine pipeline

S. Rao, J. A. Somarelli, E. Altunel, L. E. Selmic, M. Byrum, M. U. Sheth, S. Cheng, K. E. Ware, S. Y. Kim, J. A. Prinz, N. Devos, D. L. Corcoran, A. Moseley, E. Soderblom, S. D. Hsu, W. C. Eward

This paper develops a cross-species personalized medicine pipeline using canine sarcomas to identify new treatments, finding proteasome inhibitors initially effective but limited by tumor heterogeneity.

bioRxiv · Jan 10, 2019Cancer Biology